Research Analysts Issue Forecasts for BioNTech Q1 Earnings

BioNTech SE (NASDAQ:BNTX - Free Report) - HC Wainwright boosted their Q1 2025 earnings estimates for shares of BioNTech in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($2.34) per share for the quarter, up from their prior forecast of ($3.42). HC Wainwright currently has a "Buy" rating and a $145.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at ($5.51) EPS.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The company's quarterly revenue was down 19.5% on a year-over-year basis.

Several other research firms also recently weighed in on BNTX. Morgan Stanley decreased their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective for the company. Truist Financial initiated coverage on shares of BioNTech in a research report on Friday, January 10th. They set a "buy" rating and a $172.00 target price on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Finally, Citigroup started coverage on BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and an average target price of $143.44.

Remove Ads

BioNTech Trading Up 4.9 %

Shares of BioNTech stock traded up $4.29 during trading on Friday, hitting $90.94. The stock had a trading volume of 451,330 shares, compared to its average volume of 844,477. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The stock has a market cap of $21.82 billion, a PE ratio of -43.63 and a beta of 1.07. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The firm's fifty day simple moving average is $106.71 and its 200-day simple moving average is $112.23.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company's stock valued at $15,919,000 after buying an additional 74,119 shares in the last quarter. SG Americas Securities LLC boosted its stake in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company's stock worth $4,726,000 after purchasing an additional 33,375 shares in the last quarter. Mirabaud & Cie SA acquired a new stake in BioNTech in the 4th quarter worth approximately $684,000. Redmile Group LLC purchased a new stake in BioNTech during the 3rd quarter worth approximately $18,345,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 4.3% in the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after buying an additional 150 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.